Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy Controls

NCT07740551 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-08-01
Last updated
2026-07-31

Condition(s) studied

Primary Ciliary Dyskinesia (PCD)

Investigational drug(s) / intervention(s)

Physical Evaluations in Children with Primary Ciliary DyskinesiaPhysical Evaluations in Healthy Children

Physical Evaluations in Children with Primary Ciliary Dyskinesia: In this study, malnutrition and sarcopenia status in children and adolescents diagnosed with primary ciliary dyskinesia will be evaluated. All data pertaining to these assessments will be acquired via face-to-face interviews with a duration of 45 to 60 minutes.

Physical Evaluations in Healthy Children: In this study, malnutrition and sarcopenia status in children and adolescents diagnosed with primary ciliary dyskinesia will be evaluated. All data pertaining to these assessments will be acquired via face-to-face interviews with a duration of 45 to 60 minutes.

Study summary

To date, the literature has not yet elucidated the status of malnutrition and sarcopenia in children and adolescents with PCD compared to healthy controls. Therefore, the aim of this study is to compare the nutritional and sarcopenia status of children and adolescents with primary ciliary dyskinesia to that of healthy controls.

Eligibility

Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria for Children and Adolescents with Primary Ciliary Dyskinesia: * To be between the ages of 6-18 * To have been diagnosed with primary ciliary dyskinesia * To be clinically stable for at least 3 weeks * To have the necessary cooperation for the measurements * To volunteer to participate in the study Inclusion Criteria for Healthy Children and Adolescents: * To be between the ages of 6-18 * To be in a similar average and ratio with the group of children and adolescents with primary ciliary dyskinesia in terms of age and gender * To have the necessary cooperation for the measurements * To volunteer to participate in the study Exclusion Criteria for Children and Adolescents with Primary Ciliary Dyskinesia: * Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months * Smoking or quitting smoking Exclusion Criteria for Healthy Children and Adolescents: * Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months * Having any chronic disease * Smoking or quitting smoking

Primary outcome measure(s)

  • Hand Grip Strength — through study completion, an average of 1 year
    Handgrip strength (kg) will be assessed twice in each hand using a dynamometer (Jamar) with a maximal isometric contraction lasting approximately 2 seconds. The best result (kg) will be used for data analysis.

Trial sites (1)

FacilityCityRegionStatus
Izmir Democracy University Izmir Turkey (Türkiye)

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07740551 on ClinicalTrials.gov ↗ ← All trials in Turkey